BioCardia, Inc. BCDA
Last close
1.08
2026-09-04
Market cap
$16.3M
2026-06-30 share count
52-week range
0.75 - 2.29
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $58.0K | $477.0K | $1.4M | $1.0M | $145.0K | $710.0K | $625.0K | $479.0K | $576.0K |
| Cost of revenue | — | — | — | — | $0 | $4.0K | $358.0K | $517.0K | $690.0K | $746.0K |
| Gross profit | — | — | — | — | $1.0M | $141.0K | $352.0K | $108.0K | -$211.0K | -$170.0K |
| R&D | $5.0M | $4.4M | $7.7M | $8.8M | $8.6M | $9.8M | $8.6M | $8.5M | $5.8M | $3.3M |
| SG&A | $3.3M | $3.7M | $4.4M | $4.4M | $5.1M | $5.9M | $6.0M | $5.8M | $6.4M | $4.1M |
| Total operating expenses | $8.3M | $8.1M | $12.1M | $13.3M | $13.6M | $15.7M | $14.9M | $14.7M | $12.9M | $8.2M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M | -$12.6M | -$15.5M | -$14.2M | -$14.1M | -$12.4M | -$7.6M |
| Interest expense | — | — | — | — | $0 | $3.0K | $112.0K | — | $0 | $1.7M |
| Pre-tax income | -$8.2M | -$7.9M | -$11.6M | -$11.9M | -$12.6M | -$15.0M | -$14.7M | -$14.0M | -$12.3M | -$10.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M | -$12.6M | -$15.0M | -$14.7M | -$14.0M | -$12.3M | -$10.3M |
| EPS, basic | -1.23 | -2.90 | -8.19 | -0.67 | -0.75 | — | — | — | — | — |
| EPS, diluted | — | — | — | — | -0.75 | -1.48 | -2.61 | -3.28 | -2.90 | -1.23 |
| Shares, diluted (wtd. avg.) | 6.7M | 2.7M | 1.4M | 17.7M | 16.9M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.5M | $2.4M | $1.1M | $7.4M | $12.9M | $21.4M | $5.6M | $5.4M | $12.7M | $21.4M |
| Receivables | $20.0K | $0 | $63.0K | $201.0K | $147.0K | $232.0K | $147.0K | $274.0K | $95.0K | $74.0K |
| Inventory | — | — | — | — | — | — | $4.0K | $141.0K | $191.0K | $135.0K |
| Total current assets | $2.7M | $2.6M | $1.5M | $7.9M | $13.5M | $22.7M | $6.4M | $6.2M | $13.3M | $21.9M |
| Property, plant and equipment | $16.0K | $33.0K | $94.0K | $170.0K | $182.0K | $145.0K | $181.0K | $145.0K | $169.0K | $111.0K |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M | $15.7M | $23.4M | $7.7M | $6.4M | $13.5M | $22.1M |
| Accounts payable | $641.0K | $385.0K | $890.0K | $683.0K | $507.0K | $746.0K | $914.0K | $743.0K | $902.0K | $525.0K |
| Total current liabilities | $2.4M | $2.3M | $3.6M | $3.6M | $3.7M | $4.2M | $4.0M | $2.5M | $2.3M | $1.4M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M | $5.3M | $4.2M | $5.3M | $2.6M | $2.4M | $1.5M |
| Retained earnings | -$168.3M | -$160.1M | -$152.2M | -$140.6M | -$128.7M | -$116.1M | -$101.1M | -$86.4M | -$72.5M | -$60.1M |
| Total equity | $895.0K | $837.0K | -$1.6M | $4.9M | $10.4M | $19.2M | $2.4M | $3.8M | $11.1M | $20.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.4M | -$12.4M | -$9.4M | -$11.1M | -$8.7M | -$5.5M |
| Depreciation and amortisation | $24.0K | $67.0K | $84.0K | $82.0K | $60.0K | $68.0K | $111.0K | $88.0K | $78.0K | $39.0K |
| Stock-based compensation | $430.0K | $741.0K | $1.0M | $1.2M | $1.7M | $3.0M | $2.7M | $2.8M | $2.7M | $942.0K |
| Capital expenditure | $7.0K | $6.0K | $12.0K | $70.0K | $116.0K | $32.0K | $146.0K | $66.0K | $136.0K | — |
| Investing cash flow | -$7.0K | -$6.0K | -$12.0K | -$70.0K | -$116.0K | -$32.0K | -$146.0K | -$66.0K | -$136.0K | $18.9M |
| Financing cash flow | $7.6M | $9.2M | $3.7M | $5.1M | $1.9M | $28.2M | $9.8M | $3.8M | $144.0K | $4.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-009587.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $576.0K | $479.0K | $625.0K | $710.0K | $145.0K | $1.0M | $1.4M | $477.0K | $58.0K | $0 |
| Gross profit | -$170.0K | -$211.0K | $108.0K | $352.0K | $141.0K | $1.0M | — | — | — | — |
| Net income | -$10.3M | -$12.3M | -$14.0M | -$14.7M | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Delisting notice Item 3.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |